Mr. Waddill began his career 35 years ago in commercial banking and public accounting and has been in the biotechnology industry for over 30 years. He was Senior VP and CFO at both Calithera Bioscience (2014-2016) and OncoMed Pharmaceuticals (2007-2014), both of which were public clinical-stage biopharmaceutical companies. Prior to that, he served as the Senior VP and CFO of Ilypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. Before joining Ilypsa, he served as founder and principal at Square One Finance, a financial consulting business.

Currently Mr. Waddill sits on the boards of Protagonist Therapeutics (NASDAQ: PTGX) and Annexon Biosciences (NASDAQ: ANNX), both clinical-stage biopharmaceutical companies. Past board experience includes the Association of Bioscience Financial Officers (ABFO), which he chaired in 2016, and co-chaired their 2014 ABFO National Conference. He was also Chair of the Biotechnology Innovation Organization’s (BIO) Business Solutions Advisory Board as well as BIO’s Finance and Tax Committee. Mr. Waddill has also testified in Washington DC on behalf of the biotech industry in front of the Senate Finance Committee and Congressional Capital Markets Subcommittee.

William Waddill received a BS in accounting from the University of Illinois, Chicago, and a CPA license (inactive) after working at PriceWaterhouseCoopers and Deloitte in Boston.